Johnson & Johnson’s revenues
Johnson & Johnson reported revenues of ~$18.8 billion during 2Q17, reflecting 1.9% growth compared to 2Q16. The growth in revenues reached 2.9% at constant exchange rates, offset by a 1% negative impact of foreign exchange.
The chart below shows analysts’ recommendations for Johnson & Johnson over the last 12 months.
Wall Street analysts’ estimates
Wall Street analysts expect Johnson & Johnson (JNJ) to generate earnings per share (or EPS) of $1.80 on revenues of $19.3 billion in 3Q17. These figures represent 8.3% growth in revenues compared to 3Q16, resulting from the increase in sales at constant exchange rates across its three business segments.
JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date. Analysts estimate that its stock price could rise 1.5% over the next 12 months.
Analyst recommendations show a 12-month target price of $138.65 per share compared to its price of $136.65 per share on October 11, 2017.
On October 12, 2017, 23 analysts tracked Johnson & Johnson. Twelve analysts recommended a “buy,” eight analysts recommended a “hold,” and three analysts recommended a “sell.”
The consensus rating for Johnson & Johnson stands at 2.48, which represents a moderate buy for value investors. Changes in analysts’ estimates and recommendations are based on the changing trends in the company’s stock price and performance.
The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 8.2% of its total assets in Johnson & Johnson (JNJ). FTXH also has 9.0% of its total assets in Abbott Laboratories (ABT), 8.3% in Pfizer (PFE), and 4.6% of its total assets in Bristol-Myers Squibb (BMY).